RESEARCH MONOGRAPH · KDC-MN-080

Tesamorelin

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

75/100

DPP-4-resistant GHRH analog with FDA approval for HIV lipodystrophy and the cleanest visceral-fat-reduction data of any GH-axis drug

Tesamorelin is the only FDA-approved synthetic GHRH analog on the market, and the reason it cleared regulatory hurdles where sermorelin and others stalled is genuinely interesting medicinal chemistry. Theratechnologies modified the N-terminus with a trans-3-hexenoyl group attached to Tyr1, which blocks DPP-4 cleavage and extends the serum half-life to roughly 30-40 minutes from sermorelin's 10-15. Modest pharmacokinetic improvement, dramatic clinical implication.

What we like is the clinical evidence base. The phase 3 trials for HIV-associated lipodystrophy (Falutz 2007, 2010; Stanley 2011) showed reproducible visceral adipose tissue reductions of 15-18% over 26 weeks, with corresponding improvements in triglycerides and inflammatory markers. The mechanism story (restored physiological GH pulsing leading to lipolysis specifically in visceral fat, mediated partly by IGF-1 and partly by direct GH effects on adipocyte hormone-sensitive lipase) is consistent across multiple trials. This is one of the few GH-axis interventions with hard human imaging endpoints behind it.

What we dont like is the cost and the niche indication. The approved indication is narrow, the pharmaceutical product is expensive, and the broader use cases (general visceral fat, metabolic syndrome, etc.) are off-label with thinner evidence. The IGF-1 elevation is real (typically 30-70% above baseline at therapeutic doses) and chronic supraphysiological IGF-1 has the same theoretical implications it does with any GH-axis intervention.

Sourcing has improved considerably in the last few years as the molecule has come off patent in some jurisdictions. The 44-residue modified peptide is more complex than sermorelin synthetically, but reputable peptide vendors handle it now with reasonable HPLC purity. Watch for hexenoyl modification incompleteness in cheaper lots; the modified Tyr1 is the whole point.

For research on visceral adipose tissue biology and GH-axis-mediated lipolysis, tesamorelin has the best human evidence base of any compound in this category. The DPP-4-resistance modification is also a useful case study in peptide stabilization chemistry. Genuinely promising in its target indication and worth respect.

Evidence: 85
Mechanism: 88
Reliability: 82
Safety: 75
Sourcing: 72
Value: 50
Signal: 75
Staying power: 75

Plain-language summary Intrigue 70 / 100

Tesamorelin, sold as Egrifta, is a stabilized GHRH analog FDA-approved for HIV-associated visceral fat accumulation. It produces growth hormone release while preserving the natural pulsatile pattern. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Stabilized GHRH analog

A trans-3-hexenoic acid stabilized GHRH analog FDA-approved as Egrifta for HIV-associated lipodystrophy.

Abstract

Tesamorelin (Egrifta; CAS 901758-09-6; molecular weight 5135.79) is a stabilized analog of human GHRH developed by Theratechnologies (Canada) and approved by the FDA in 2010 for HIV-associated lipodystrophy. The structural modification is the addition of a trans-3-hexenoic acid group at the N-terminus, which substantially extends plasma half-life relative to native GHRH or sermorelin. The compound stimulates physiological GH release with restored visceral adipose tissue reduction in HIV patients on antiretroviral therapy. Pharmacokinetics: plasma half-life approximately 26 minutes (versus 11 to 12 minutes for sermorelin); subcutaneous administration. Reported research dose ranges in the literature are around 2 mg subcutaneously.

Mechanism of action

Stabilized GHRH receptor agonist with extended half-life (trans-3-hexenoic acid N-terminal modification).

Reported research dose ranges

2 mg SC (reported research dose ranges in the literature).

References

Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, on visceral adipose tissue accumulation in HIV-infected patients. J Clin Endocrinol Metab 2010.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-080

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Tesamorelin

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs